Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions: Metformin XR plus placebo, Metformin XR plus liraglutide; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions: Nicotinamide riboside (NR), Placebo; Dietary Supplement · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 39 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure, Congestive Heart Failure, Diabetes, Diabetes Mellitus, Chronic Kidney Diseases
Interventions: Care Transitions App; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years and older
Enrollment: 798 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus Type 2, Hyperglycemia
Interventions: Glipizide XL, Saxagliptin + Metformin XR, Metformin XR; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes
Interventions: NUTRI-Beta Counseling, Standard dietary counseling, Free weekly produce foods; Other · Dietary Supplement
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Hershey, Pennsylvania

Conditions: Ovarian Cancer
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Papillary Thyroid Microcarcinoma
Interventions: Active Surveillance; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes
Interventions: Saxagliptin, Metformin, Placebo, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Concord, California • Encinitas, California • Orange, California + 38 more

Conditions: Stress, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Mindfulness Based Stress Reduction, Stress Management Education; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Cancer Ovaries, Cancer Peritoneal, Cancer, Fallopian Tube
Interventions: OMP-305B83, Paclitaxel; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Aurora, Colorado • Tampa, Florida • Charlotte, North Carolina + 4 more

Conditions: Type 2 Diabetes
Interventions: glargine, detemir; Drug
Lead sponsor: Diabetes Care Center; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Salinas, California

Conditions: Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
Interventions: COM701, COM701 with Opdivo (Nivolumab).; Drug
Lead sponsor: Compugen Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more

Conditions: Hypothyroidism
Interventions: Isovue; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: Up to 3 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Phoenix, Arizona • Omaha, Nebraska • Akron, Ohio + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Oregon Research Institute; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Type 2 Diabetes Mellitus
Interventions: PHX1149T, Placebo; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Norwalk, California • Orange, California • Santa Ana, California + 10 more

Conditions: Pancreas Neoplasm Malignant Resectable
Interventions: Folfox6, Gemcitabine, Radiation Therapy, Pancreaticoduodenectomy with retroperitoneal lymphadenectomy; Drug · Radiation · Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cystic Fibrosis Related Bone Disease
Interventions: Estradiol 2 mg, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV I Infection
Interventions: Our Family, Our Voices; Behavioral
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Type 2 Diabetes
Interventions: Salsalate, Placebo; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 16
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Winter Park, Florida + 12 more

Conditions: Diabetes Mellitus
Interventions: Dexcom G7 Continuous Glucose Monitor; Diagnostic Test
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Thyroid Eye Disease (TED)
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Birmingham, Alabama • Escondido, California • Fresno, California + 54 more

Conditions: Type 1 or Type 2 Diabetes
Interventions: Bigfoot Unity Diabetes Management System; Device
Lead sponsor: Bigfoot Biomedical Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Milpitas, California

Conditions: HbA1c, Diabetes
Interventions: Community Health Worker (CHW)-Led Health Coaching, EHR-Embedded Alerts; Behavioral · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 75 Years
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

Care Transitions App for Patients With Multiple Chronic Conditions

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D)

Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families

Active Surveillance of Papillary Thyroid Microcarcinoma

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Decreasing Stress in Diabetes

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Thyroid Function of Pediatric Subjects Following Isovue® Administration

Enhancing Support for Women With Type 2 Diabetes: Follow-Up

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Pilot E2 for Hypogonadal Women With CFBD

Leveraging Family-Based Assets for Black MSM In House Ball Communities

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

Continuous Glucose Monitoring in the Intensive Care Unit

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Bigfoot Unity Real World Study

Diabetes Management Intervention For South Asians